Being isolated on the island of Mauritius since the introduction of a small founder population, 400 years ago, the local Cynomolgus macaques have developed a unique genetic profile. They have never been hybridised with any other macaque species. This also means that they are free from diseases that typically affect macaques in other regions of the world.
Medical research carried out with the help of cynomolgus macaques from Mauritius enables better reproducibility in the results. These macaques are thus most suitable candidates for cancer, diabetes, HIV, gene and stem cell therapies among many other research fields.
All our 9 sites in Mauritius and 3 in the US implement the highest standards of animal welfare, veterinary care and husbandry. All our operations are AAALAC accredited and ISO certified while our housing facilities strictly comply with European ETS 123 norms.
A unique feature of sourcing cynomolgus macaques from Mauritius is that they are not endemic to the island, having been introduced by early settlers in the 17th century. Given their status as an alien species and the lack of natural predators available to control the population, the macaque breeding sector represents an important opportunity to manage the threat they represent to the endemic biodiversity in Mauritius. Bioculture (Mauritius) Ltd has consistently focussed an important share of its corporate social investments to supporting biodiversity initiatives.